MedTrace Logo

Songling Xuemaikang in Hypertension and Insomnia Evaluation（SHINE）

NCT07709442 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2026-07-16

No results posted yet for this study

Summary

To evaluate the effect of Songling Xuemaikang Capsules on reducing 24-hour mean blood pressure in patients with hypertension accompanied by insomnia.

Conditions

Interventions

DRUG

Songling Xuemaikang Capsule

3 capsules each time, 3 times a day, for 12 consecutive weeks.

DRUG

Songling Xuemaikang Capsule Simulant

Songling Xuemaikang Capsule Simulant, 3 capsules each time, 3 times a day, for 12 consecutive weeks.

Sponsors & Collaborators

  • Chengdu Kanghong Pharmaceutical Group Co., Ltd.

    collaborator INDUSTRY

  • Jing Liu

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-06-30
Completion
2028-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07709442 on ClinicalTrials.gov